The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
DNA Origami Delivery System for Cancer Therapy with Tunable Release Properties
Open accessAbstract
In the assembly of DNA nanostructures, the specificity of Watson-Crick base pairing is used to control matter at the nanoscale. Using this technology for drug delivery is a promising route toward the magic bullet concept, as it would allow the realization of complex assemblies that co-localize drugs, targeting ligands and other functionalities in one nanostructure. Anthracyclines' mechanism of action in cancer therapy is to intercalate DNA, and since DNA nanotechnology allows for such a high degree of customization, we hypothesized that this would allow us to tune the DNA nanostructures for optimal delivery of the anthracycline doxorubicin (Dox) to human breast cancer cells. We have tested two DNA origami nanostructures on three different breast cancer cell lines (MDA-MB-231, MDA-MB-468, and MCF-7). The different nanostructures were designed to exhibit varying degrees of global twist, leading to different amounts of relaxation in the DNA double-helix structure. By tuning the nanostructure design we are able to (i) tune the encapsulation efficiency and the release rate of the drug and (ii) increase the cytotoxicity and lower the intracellular elimination rate when compared to free Dox. Enhanced apoptosis induced by the delivery system in breast cancer cells was investigated using flow cytometry. The findings indicate that DNA origami nanostructures represent an efficient delivery system for Dox, resulting in high degrees of internalization and increased induction of programmed cell death in breast cancer cells. In addition, by designing the structures to exhibit different degrees of twist, we are able to rationally control and tailor the drug release kinetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Cited by
Seeman, N. C., & Sleiman, H. F. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.68 · Cited by 1,875
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Dey, S., Fan, C., Gothelf, K. V., Li, J., Lin, C., Liu, L., Liu, N., Nijenhuis, M. A. D., Saccà, B., Simmel, F. C., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-020-00009-8 · Cited by 742
Supramolecular self-assemblies as functional nanomaterials
Busseron, E., Ruff, Y., Moulin, E., & Giuseppone, N. (2013) · Nanoscale · doi:10.1039/c3nr02176a · Cited by 701
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy
Qin, W., Huang, G., Chen, Z., & Zhang, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00001 · Cited by 656
Wang, F., Lu, C.-H., & Willner, I. (2014) · Chemical Reviews · doi:10.1021/cr400354z · Cited by 649
DNA nanotechnology from the test tube to the cell
Chen, Y.-J., Groves, B., Muscat, R. A., & Seelig, G. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.195 · Cited by 594
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Smart Drug Delivery Nanocarriers with Self‐Assembled DNA Nanostructures
Li, J., Fan, C., Pei, H., Shi, J., & Huang, Q. (2013) · Advanced Materials · doi:10.1002/adma.201300875 · Cited by 441
The Beauty and Utility of DNA Origami
Wang, P., Meyer, T. A., Pan, V., Dutta, P. K., & Ke, Y. (2017) · Chem · doi:10.1016/j.chempr.2017.02.009 · Cited by 345
The biological applications of DNA nanomaterials: current challenges and future directions
Ma, W., Zhan, Y., Zhang, Y., Mao, C., Xie, X., & Lin, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00727-9 · Cited by 331
Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery
Sun, W., Jiang, T., Lu, Y., Reiff, M., Mo, R., & Gu, Z. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5088024 · Cited by 329
Nanoscale Self-Assembly for Therapeutic Delivery
Yadav, S., Sharma, A. K., & Kumar, P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00127 · Cited by 324
Acoustically Propelled Nanomotors for Intracellular siRNA Delivery
Esteban-Fernández de Ávila, B., Angell, C., Soto, F., Lopez-Ramirez, M. A., Báez, D. F., Xie, S., Wang, J., & Chen, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b01415 · Cited by 309
Virus-Encapsulated DNA Origami Nanostructures for Cellular Delivery
Mikkilä, J., Eskelinen, A.-P., Niemelä, E. H., Linko, V., Frilander, M. J., Törmä, P., & Kostiainen, M. A. (2014) · Nano Letters · doi:10.1021/nl500677j · Cited by 308
Framework nucleic acids as programmable carrier for transdermal drug delivery
Wiraja, C., Zhu, Y., Lio, D. C. S., Yeo, D. C., Xie, M., Fang, W., Li, Q., Zheng, M., Van Steensel, M., Wang, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09029-9 · Cited by 294
Challenges and Perspectives of DNA Nanostructures in Biomedicine
Keller, A., & Linko, V. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201916390 · Cited by 285
Visualization of the Cellular Uptake and Trafficking of DNA Origami Nanostructures in Cancer Cells
Wang, P., Rahman, M. A., Zhao, Z., Weiss, K., Zhang, C., Chen, Z., Hurwitz, S. J., Chen, Z. G., Shin, D. M., & Ke, Y. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09024 · Cited by 269
A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy
Liu, J., Song, L., Liu, S., Jiang, Q., Liu, Q., Li, N., Wang, Z.-G., & Ding, B. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04812 · Cited by 267
Smart Nanocarriers for the Delivery of Nucleic Acid‐Based Therapeutics: A Comprehensive Review
Ramasamy, T., Munusamy, S., Ruttala, H. B., & Kim, J. O. (2021) · Biotechnology Journal · doi:10.1002/biot.201900408 · Cited by 76
Static DNA Nanostructures For Cancer Theranostics: Recent Progress In Design And Applications
Jahanban-Esfahlan, R., Seidi, K., Jahanban-Esfahlan, A., Jaymand, M., Alizadeh, E., Majdi, H., Najjar, R., Javaheri, T., & Zare, P. (2019) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s227193 · Cited by 50
Kohman, R. E., Kunjapur, A. M., Hysolli, E., Wang, Y., & Church, G. M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201707976 · Cited by 33
Targeted delivery of Rab26 siRNA with precisely tailored DNA prism for lung cancer therapy
Liu, Q., Wang, D., Xu, Z., Huang, C., Zhang, C., He, B., Mao, C., Wang, G., & Qian, H. (2019) · ChemBioChem · doi:10.1002/cbic.201800761 · Cited by 30
Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective
Li, X., Zhang, Y., Wang, C., Wang, L., Ye, Y., Xue, R., Shi, Y., Su, Q., Zhu, Y., & Wang, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01480 · Cited by 4
Metadata
- Authors
- Zhao, Y.-X., Shaw, A., Zeng, X., Benson, E., Nyström, A. M., & Högberg, B.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-09-13
- Volume
- 6
- Issue
- 10
- Pages
- 8684-8691
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2313837144
- Cited by
- 519
- References
- 1
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.